Strides Pharma Science India informs about updates

19 May 2023 Evaluate

Strides Pharma Science India has informed that the company has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Puducherry manufacturing facility (Facility), stating the inspection conducted between February 20-24, 2023 has been closed. The USFDA has classified the facility from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI). The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019. Strides Puducherry facility caters to the US, other regulated markets, and institutional businesses and produces finished dosage formulation products across multiple dosage formats. Consequent to this reclassification by the USFDA, the filed ANDAs from this facility will now start receiving approvals. The Company remains committed to the highest standards of compliance and will continue to focus on manufacturing high-quality pharmaceutical products for the Global markets.

The above information is a part of company’s filings submitted to BSE.

Strides Pharma Scien Share Price

828.20 -21.70 (-2.55%)
14-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 984.75
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.